东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01875 东曜药业-B

未开盘 01-15 16:08:08

4.190

+1.690

+67.60%

最高4.450	最低3.870	成交量4,226万
今开3.970	昨收2.500	日振幅23.20%
总市值32.39亿	流通市值32.38亿	总股本7.73亿
成交额1.72亿	换手率5.47%	流通股本7.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":4.19,"timestamp":1768464488278,"preClose":2.5,"halted":0,"volume":42263000,"delay":0,"changeRate":0.6760000000000002,"floatShares":772787887,"shares":773000000,"eps":0.047927,"marketStatus":"未开盘","change":1.69,"latestTime":"01-15 16:08:08","open":3.97,"high":4.45,"low":3.87,"amount":172167070,"amplitude":0.232,"askPrice":4.19,"askSize":169200,"bidPrice":4.18,"bidSize":8800,"shortable":0,"etf":0,"ttmEps":-0.006,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768527000000},"marketStatusCode":0,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":2.5,"openAndCloseTimeList":[[1768440600000,1768449600000],[1768453200000,1768464000000]],"volumeRatio":71.235983,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"2603266625","title":"东曜药业-B(01875)1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603266625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603266625?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:45","pubTimestamp":1768437900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，公司股份将于2026年1月15日上午9时正起恢复买卖。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2603462820","title":"智通港股早知道 | 财政部召开财政金融协同促内需会议 白宫宣布对特定半导体等加征25%关税","url":"https://stock-news.laohu8.com/highlight/detail?id=2603462820","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603462820?lang=zh_cn&edition=full","pubTime":"2026-01-15 07:40","pubTimestamp":1768434028,"startTime":"0","endTime":"0","summary":"参加会议的包括国务院有关部门和单位、省级财政部门、财政部各地监管局以及相关经办机构。美国白宫宣布对特定半导体等加征25%关税美国白宫14日宣布，从15日起对部分进口半导体、半导体制造设备和衍生品加征25%的进口从价关税。根据该通知书，市监总局已根据中华人民共和国反垄断法开始对本公司进行调查。经本公司财务部门初步测算，预计2025年度实现归属于上市公司股东的扣除","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1189","09961","BK1521","BK4588","BK4585","BK1571","BK1502","BK1584","BK1142","BK1564","09688","BK1501","BK1615","SMH","BK1247","BK1147","BK1591","01875","03759","BK1515","LU1720050803.USD","300759","02269","LU1794554557.SGD","BK1589","TCOM","02268","BK1516","SOXX","WXXWY","BK1610","ZLAB","BK1617"],"gpt_icon":1},{"id":"2603157617","title":"港股公告掘金 | 东曜药业-B获药明合联溢价约99%提现金要约 1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603157617","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603157617?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:05","pubTimestamp":1768403110,"startTime":"0","endTime":"0","summary":"重大事项：龙旗科技(09611)1月14日至1月19日招股 拟全球发售5225.91万股H股和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表东阳光药(06887)推出面向PROTAC机制的AI智能研发平台 持续深化AI战略布局东曜药业-B(01875)获药明合联(02268)溢价约99%提现金要约 1月15日复牌维立志博-B(09887)：维利信(P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1516","BK1564","LU1497734951.SGD","LU1634259391.SGD","LU0051755006.USD","06030","LU1794554557.SGD","LU1522347837.USD","HK0000252152.HKD","LU0572940350.SGD","09887","BK1574","LU2488822045.USD","HK0000500386.USD","BK1161","LU0210526637.USD","SG9999014674.SGD","BK1141","BK1191","00998","BK1521","LU1634259557.SGD","02268","LU0572939691.SGD","LU1497733557.USD","HK0000252160.HKD","BK1147","LU0264606111.USD","01875","BK1560","BK1231","LU0456827905.SGD","LU1720050803.USD","LU1497733631.SGD","06887"],"gpt_icon":0},{"id":"2603617932","title":"东曜药业-B(01875)获药明合联(02268)溢价约99%提现金要约 1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603617932","media":"智通财经","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603617932?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:02","pubTimestamp":1768402952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 及要约人药明合联联合公布，于2026年1月14日，董事会获要约人告知，花旗将为及代表要约人作出自愿有条件现金要约，以每股要约股份4港元的价格收购全部已发行股份，并注销全部尚未行使购股权。要约价较股份于未受干扰日在联交所所报收市价每股2.01港元溢价约99.00%。公司已向联交所申请自2026年1月15日上午九时正起恢复股份于联交所买卖。要约人拟于完成后维持股份于联交所上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东曜药业-B获药明合联溢价约99%提现金要约，1月15日复牌","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01875","BK1141","02268","LU2488822045.USD","SG9999014674.SGD","BK1574"],"gpt_icon":1},{"id":"1191815089","title":"东曜药业-B向港交所提交申请 股票将于1月15日恢复交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1191815089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191815089?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:57","pubTimestamp":1768402630,"startTime":"0","endTime":"0","summary":"东曜药业-B（股票代码：01875）已正式向香港联合交易所提交申请，请求自2024年1月15日起恢复公司股份的买卖交易。此次申请标志着公司在满足相关监管要求后，正积极推动股票交易的正常化进程。若获批复，投资者将可于下周一重新在公开市场进行该股票的买卖操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"1147379811","title":"东曜药业-B：药明合联拟全面收购公司非其持有之全部已发行股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1147379811","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147379811?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:55","pubTimestamp":1768402526,"startTime":"0","endTime":"0","summary":"东曜药业-B（BIODLINK-B）近日披露重大收购要约，药明合联（WuXi XDC Cayman）计划收购公司全部已发行股份中非其已持有的部分。\n此次要约标志着药明合联对东曜药业-B的战略整合迈出关键一步，或将重塑公司股权结构。市场密切关注此次收购对东曜药业-B未来业务发展和市场定位的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2595279964","title":"停牌！CEO离任，业绩下滑，biotech有新交易？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595279964","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595279964?lang=zh_cn&edition=full","pubTime":"2025-12-30 00:13","pubTimestamp":1767024785,"startTime":"0","endTime":"0","summary":"任何文章转载需得到授权。药融圈监测显示：东曜药业-B发布公告，公司的股份将于2025年12月29日上午九时正起短暂停止买卖。此前在8月12日，东曜药业发布截至2025年6月30日的中期业绩公告，业绩显示公司营业收入为4.89亿元，同比下降6%。CDMO/CMO业务收入为7730万元，同比下降32%，主要是由于部分关键项目尚未达到交付节点。2016 年 10 月至 2025 年 10 月于东曜药业股份有限公司担任副总经理、首席科学家、首席执行官、执行董事。离开后任职纳微。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230001828a486c140&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230001828a486c140&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"2593434752","title":"东曜药业-B12月22日主力净流出14.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593434752?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391313,"startTime":"0","endTime":"0","summary":"12月22日, 东曜药业-B股价跌0.99%，报收2.01元，成交金额61.7万元，换手率0.04%，振幅4.43%，量比0.93。东曜药业-B今日主力资金净流出14.1万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.52%，主力资金累计净流入32.9万元；近20日主力资金累计净流入100.6万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161548a6c084bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161548a6c084bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2593121463","title":"东曜药业-B(01875)授出1335万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593121463","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593121463?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:15","pubTimestamp":1766312109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，2025年12月19日，管理委员会已议决根据2024年受限制股份奖励计划作出授出，共涉及1335万股奖励股份，每股奖励股份0.6港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2589083332","title":"东曜药业-B12月08日主力净流入14.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2589083332","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589083332?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181728,"startTime":"0","endTime":"0","summary":"12月08日，东曜药业-B股价收平报1.71元，成交金额32.2万元，换手率0.02%，振幅2.92%，量比2.71。东曜药业-B今日主力资金净流入14.3万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.16%，主力资金累计净流入14.3万元；近20日主力资金累计净流入67.7万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208161708a72aa45a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208161708a72aa45a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"1140957185","title":"东曜药业（1875）11月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1140957185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140957185?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:16","pubTimestamp":1764839781,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司（01875）于2025年12月4日发布11月股份变动月报，报告期为2025年11月1日至11月30日。公司披露，截至本月末，已发行股份总数为772,787,887股，与上月持平，未有新增发行、购回或注销股份行为。\n公司同时披露有关股份期权计划情况：期末总计7,759,600股期权维持不变，本月内未有授出、行使或失效事宜。截至2025年11月30日，公司股本及发行在外股份数保持稳定。\n公告显示，公司确认已遵守香港联合交易所有限公司《上市规则》和相关法律规定。月报由联席公司秘书吕颖一签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2586382294","title":"东曜药业-B11月26日主力净流入53.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586382294","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586382294?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:15","pubTimestamp":1764144906,"startTime":"0","endTime":"0","summary":"11月26日，东曜药业-B股价收平报1.78元，成交金额63.0万元，换手率0.05%，振幅3.37%，量比9.08。东曜药业-B今日主力资金净流入53.4万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.30%，主力资金累计净流入53.4万元；近20日主力资金累计净流入53.4万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161522a4bb5364&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161522a4bb5364&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01875","BK1574"],"gpt_icon":0},{"id":"2585113379","title":"2025年国产药物出海大爆发，获批上市捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113379","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113379?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:41","pubTimestamp":1763710901,"startTime":"0","endTime":"0","summary":"2025年国产药物出海以 License - out 为代表的 BD 交易就已迎来跨越式增长。资料显示，截至10月份，2025年中国创新药BD交易总额已超过千亿美元。值得一提的是，截至目前，复宏汉霖已有7款产品于海外获批上市，其中4款产品在美国获批上市。10月下旬，东曜药业宣布贝伐珠单抗生物类似药正式获得玻利维亚国家药品与卫生技术局批准上市，此次获批是贝伐珠单抗在海外上市的第五个国家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121154551a4b10ab6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121154551a4b10ab6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2583316485","title":"东曜药业：前三季度营收为6.22亿元，自研产品市场竞争愈加激烈","url":"https://stock-news.laohu8.com/highlight/detail?id=2583316485","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583316485?lang=zh_cn&edition=full","pubTime":"2025-11-12 18:32","pubTimestamp":1762943559,"startTime":"0","endTime":"0","summary":"近日，东曜药业发布公告称，截至2025年9月30日止九个月，公司营业收入为6.22亿元，较去年同期下降23%，主要原因是自研产品的市场竞争愈加激烈。净利润方面，公司在此期间出现亏损，净亏损为337万元，而去年同期则实现净利润3540万元。在资产负债表方面，截至2025年9月30日，公司流动资产为6.56亿元，非流动资产为7.21亿元，流动负债为2.66亿元，非流动负债为3.85亿元，净资产总额为7.26亿元，较2024年12月31日的7.3亿元略有下降。此次财务数据为未经过审计，可能会在进一步内部审阅后进行调整。（东曜药业公告）(编辑：杨燕 林辰)关键字： 医疗","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111218353694ffb348&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111218353694ffb348&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2582935057","title":"东曜药业-B(01875)前三季度营业收入6.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582935057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582935057?lang=zh_cn&edition=full","pubTime":"2025-11-11 18:10","pubTimestamp":1762855852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，截至2025年9月30日止九个月期间，集团的营业收入为人民币6.22亿元；期内及公司权益持有人应占净亏损337.1万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875"],"gpt_icon":0},{"id":"2576003678","title":"东曜药业高管变动，CEO兼CSO辞职！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576003678","media":"药融圈","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576003678?lang=zh_cn&edition=full","pubTime":"2025-10-19 10:32","pubTimestamp":1760841144,"startTime":"0","endTime":"0","summary":"10月13日晚，东曜药业发布公告，付山先生自2025年10月11日起由公司非执行董事调任为执行董事，并负责领导并监督本集团的管理与发展，并继续担任公司董事长。黄纯莹女士，于2010年7月5日加入东曜药业股份有限公司，并于2016年1月19日获委任为东曜药业股份有限公司执行董事。彼现时担任东曜药业股份有限公司执行董事兼总经理。于2020年10月15日委任为东曜药业股份有限公司董事会副主席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019110830a4674f8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019110830a4674f8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2575974125","title":"东曜药业：CEO刘博士与副董事长黄女士因家庭原因辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2575974125","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575974125?lang=zh_cn&edition=full","pubTime":"2025-10-16 17:33","pubTimestamp":1760607212,"startTime":"0","endTime":"0","summary":"10月16日，东曜药业（01875）发布公告，因个人原因，刘博士辞任公司执行董事、首席执行官、首席科学官及战略与ESG委员会成员，黄女士辞任公司非执行董事、副董事长及战略与ESG委员会成员。公告补充说明，刘博士及黄女士均因家庭原因辞任上述职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016173420a46304c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016173420a46304c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2575741283","title":"这家医药CDMO企业CEO离职！ ADC赛道的战略抉择","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741283","media":"中国制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575741283?lang=zh_cn&edition=full","pubTime":"2025-10-16 10:02","pubTimestamp":1760580149,"startTime":"0","endTime":"0","summary":"CDMO/CMO业务收入人民币207,133千元，同比增长47%。得益于公司高效的研发平台，报告期内东曜药业协助客户完成获批临床的双载荷ADC项目。东曜药业表示，主要原因为部分关键项目尚未达到交付节点。对于聚焦 ADC 赛道的东曜而言，管理层更迭恰逢行业竞争关键期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101610104394cc03c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101610104394cc03c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","BK1574","01875"],"gpt_icon":0},{"id":"2575414027","title":"年薪超五百万！这一药企CEO辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2575414027","media":"医药代表","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575414027?lang=zh_cn&edition=full","pubTime":"2025-10-16 07:12","pubTimestamp":1760569927,"startTime":"0","endTime":"0","summary":"10 月 13 日，东曜药业股份有限公司发布公告，宣布了多个高管人事变动。除此之外，自 2025 年 10 月 11 日起，付山由东曜药业非执行董事调任为执行董事，并负责领导并监督东曜药业的管理与发展。据公告，刘军、黄纯莹两人辞任后将获聘为东曜药业策略顾问。2020 年 10 月 15 日，刘军被任命为东曜药业首席执行官。据公开信息，刘军 2023 年在东曜药业薪酬总额为 752.8 万元，2023 年薪酬总额为 566.3 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101607203294cbb5cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101607203294cbb5cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01875","BK1574"],"gpt_icon":0},{"id":"2575747683","title":"东曜药业-B(01875)：付山由非执行董事调任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2575747683","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575747683?lang=zh_cn&edition=full","pubTime":"2025-10-13 16:46","pubTimestamp":1760345218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布公告，付山先生自2025年10月11日起由公司非执行董事调任为执行董事，并负责领导并监督集团的管理与发展。继刘博士离任董事后，付先生已根据上市规则第3.05条的规定获委任为公司授权代表以接替刘博士，该委任自2025年10月11日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01875","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":0.676},{"period":"1month","weight":1.1598},{"period":"3month","weight":0.9952},{"period":"6month","weight":1.1937},{"period":"1year","weight":1.2649},{"period":"ytd","weight":0.676}],"compareEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.0669},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0845},{"period":"1year","weight":0.396},{"period":"ytd","weight":0.0505}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.040017},{"month":2,"riseRate":0,"avgChangeRate":-0.043389},{"month":3,"riseRate":0.5,"avgChangeRate":-0.024422},{"month":4,"riseRate":0.833333,"avgChangeRate":0.069994},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07905},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001367},{"month":7,"riseRate":0.333333,"avgChangeRate":0.023634},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.052288},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011349},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.714286,"avgChangeRate":0.042078}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}